Interleukines Results from Clinical Trial for Long COVID Treatment after supplementation with Dietary Supplement based on Sea Urchin Eggs Extract NCT05531019

Abstract

Patients with Long COVID experience a significant decrease in their quality of life and the lack of effective treatment represents an unmet need in medical care and patient health. One proposed strategy for treating Long COVID is to increase the body's ability to restore immune balance by controlling inflammation with anti-inflammatory substances. For this reason, the aim of this double-blind study was to evaluate the supplementation of patients with EchA Marine®, a dietary supplement based on sea urchin eggs rich in Echinochrome A. This compound has demonstrated anti-inflammatory and antioxidant properties by activating the metabolism of glutathione and improving mitochondrial mass and performance. In this multicenter, double-blind, intervention study, we have demonstrated that the dietary supplement EchA Marine® can significantly improve anti inflammatory interleukines and diminish pro inflamatory interleukines. EchA Marine® is an effective treatment option for Long COVID patients and with further research its efficacy could be further strengthened. Clinical trial registration number: NCT05531019. First posted September 7th, 2022.